Last reviewed · How we verify
CREON (LIPASE)
CREON (generic name: LIPASE) is a Vitamin C [EPC] drug developed by ABBVIE. It is currently FDA-approved.
CREON is a medication that belongs to the class of hydrolytic enzymes, specifically targeting fatty acids. It is used to treat conditions such as pancreatic insufficiency, pancreatic cancer, and postprandial symptoms like bloating and belching.
At a glance
| Generic name | LIPASE |
|---|---|
| Sponsor | ABBVIE |
| Drug class | Vitamin C [EPC] |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
- Headache
- Contusion
- Cough
- Early Satiety
- Abdominal Pain
- Steatorrhea
- Abdominal Distension
- Diarrhea
- Flatulence
- Constipation
- Nausea
Serious adverse events
- Fibrosing Colonopathy
- Distal Intestinal Obstruction Syndrome
- Anaphylaxis
- Asthma
- Hives
- Hyperuricemia
- Hypersensitivity Reactions
- Irritation of the Oral Mucosa
- Blurred Vision
- Asymptomatic Elevations of Liver Enzymes
Key clinical trials
- A Multicentre Open-label Phase IIa Study With Escalating Dose of MS1819- SD, to Investigate the Efficacy and Safety of a Yarrowia Lipolytica Lipase Preparation for the Compensation of Exocrine Pancrea (Phase 2)
- A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled, Phase III Study to Assess the Safety and Efficacy of Viokase® 16 for the Correction of Steatorrhea in Patients With Exocrine Panc (Phase 3)
- Study of Pharmacodynamic Equivalence of Two Commercial Formulations of Orlistat (Lipiblock vs Xenical) on Intestinal Lipases Inhibition (NA)
- Study of Pancreatic Enzymes in the Drains as Early Biomarkers of Post-operative Pancreatic Fistula and Its Clinical Repercussions (N/A)
- A Retrospective Natural History Study of Patients With Lysosomal Acid Lipase Deficiency/Wolman Phenotype (N/A)
- A Randomized, Double-blind, Placebo-controlled, Investigator-initiated Study to Assess the Additional Weight Loss Effect of Orlistat Used in Combination With Sibutramine (NA)
- A Phase II Study of Pancreatic Enzyme Replacement (Zenpep) on Completion Rates of Adjuvant Chemotherapy Among Subjects With Resected Pancreatic Ductal Adenocarcinoma (Phase 2)
- The Frequency of Cholesteryl Ester Storage Disease in Children With Unexplained Transaminase Elevation and Chronic Liver Disease (N/A)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CREON CI brief — competitive landscape report
- CREON updates RSS · CI watch RSS
- ABBVIE portfolio CI
Frequently asked questions about CREON
What is CREON?
Who makes CREON?
What is the generic name of CREON?
What drug class is CREON in?
What development phase is CREON in?
What are the side effects of CREON?
Related
- Drug class: All Vitamin C [EPC] drugs
- Manufacturer: ABBVIE — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing